1. Home
  2. MPU vs BCDA Comparison

MPU vs BCDA Comparison

Compare MPU & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MPU

Mega Matrix Corp.

N/A

Current Price

$3.04

Market Cap

14.6M

ML Signal

N/A

Logo BioCardia Inc.

BCDA

BioCardia Inc.

N/A

Current Price

$1.03

Market Cap

15.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MPU
BCDA
Founded
1989
N/A
Country
Singapore
United States
Employees
N/A
21
Industry
Transportation Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.6M
15.4M
IPO Year
2023
2009

Fundamental Metrics

Financial Performance
Metric
MPU
BCDA
Price
$3.04
$1.03
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
★ $15.50
AVG Volume (30 Days)
79.1K
★ 237.4K
Earning Date
10-06-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $479,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.17
$0.75
52 Week High
$3.88
$1.80

Technical Indicators

Market Signals
Indicator
MPU
BCDA
Relative Strength Index (RSI) 68.96 42.83
Support Level $0.51 $0.80
Resistance Level $3.88 $1.29
Average True Range (ATR) 0.23 0.09
MACD 0.03 -0.02
Stochastic Oscillator 65.50 7.67

Price Performance

Historical Comparison
MPU
BCDA

About MPU Mega Matrix Corp.

Mega Matrix Inc is a holding company that offers investors an opportunity to participate in the growth of stablecoins, one of the fastest-evolving sectors in digital assets. The company generated revenue from the Membership and top-up streaming services revenue, Online advertising services, and Content licensing. Geographically, the company operates in the United States and Canada, Asia Pacific, Europe middle east and Africa, and Latin America.

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Share on Social Networks: